Vaccines for preventing Japanese encephalitis

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2007, Pages

  Schiøler, Karin L ^a   Samuel, M ^b   Wai, K L ^b  

^a LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^b NONE

Author keywords

Encephalitis, Japanese *prevention control ; Japanese encephalitis vaccines adverse effects; immunology; *therapeutic use ; Randomized controlled trials as topic; Vaccines, attenuated adverse effects; immunology; therapeutic use

Indexed keywords

PLACEBO; TYPHOID VACCINE;

CLINICAL TRIAL; COCHRANE LIBRARY; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; EMBASE; FEVER; HUMAN; INFECTION PREVENTION; INJECTION SITE PAIN; MEDLINE; NAUSEA; REVIEW; TYPHOID FEVER; VACCINATION; VOMITING;

EID: 37249011434     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004263.pub2     Document Type: Review

References (110)

1. Hoke 1988 {published and unpublished data} Hoke CH. Lessons from field testing of non-HIV vaccines: A field trial of Japanese encephalitis vaccine in Thailand. AIDS Research and Human Retroviruses 1993;9 Suppl 1:161-7.
2. *Hoke CH, Nisalak A, Sangawhipa N, Jatanasen S, Laorakapongse T, Innis BL, et al.Protection against Japanese encephalitis by inactivated vaccines. New England Journal of Medicine 1988;319(10):608-14.
3. Hsu 1971 {published data only} *Hsu TC, Chow LP, Wei HY, Chen CL, Hsu ST. A controlled field trial for an evaluation of effectiveness of mouse-brain Japanese encephalitis vaccine. Taiwan Yi Xue Hui Za Zhi 1971;70(2):55-62.
4. Hsu TC, Chow LP, Wei HY, Chen CL, Hsu ST, Huang CT, et al.A completed field trial for an evaluation of the effectiveness of mouse-brain Japanese encephalitis vaccine. Conference on Japanese encephalitis virus vaccine. Tokyo: Igaku Shoin Ltd, 1971:258-65.
5. Hsu TC, Hsu ST. Supplementary report. Effectiveness of Japanese encephalitis vaccine: Study in the second year following vaccination. Conference on Japanese encephalitis virus vaccine. Tokyo: Igaku Shoin Ltd, 1971:266-7.
6. Kuzuhara 2003 {published data only} Kuzuhara S, Nakamura H, Hayashida K, Obata J, Abe M, Sonoda K, et al.Non-clinical and phase I clinical trials of a Vero cell-derived inactivated Japanese encephalitis vaccine. Vaccine 2003;21(31):4519-26.
7. Liu 1997 {published data only} Liu ZL, Hennessy S, Strom BL, Tsai TF, Wan CM, Tang S, C, et al.Short-term safety of live attenuated Japanese encephalitis vaccine (SA14-14-2): results of a randomized trial with 26,239 subjects. Journal of Infectious Diseases 1997;176(5):1366- 9.
8. Lyons 2004 {published data only} Lyons AG, Kuschner RA, Putnak JR, Eckels KH, Sun W, Towle AC, et al.Long term immunogenicity results of a phase 2 study of purified, inactivated vaccine against Japanese encephalitis virus (IC51, JE-PIV). American Society of Tropical Medicine and Hygiene, 53rd Annual Meeting. 2004.
9. Monath 2002b {published data only} Monath TP, McCarthy K, Bedford P, Johnson CT, Nichols R, Yoksan S, et al.Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. Vaccine 2002;20(7-8):1004-18.
10. Monath 2003 {published data only} Monath TP, Guirakhoo F, Nichols R, Yoksan S, Schrader R, Murphy C, et al.Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. Journal of Infectious Diseases 2003;188(8):1213-30.
11. Rojanasuphot 1989 {published data only} Rojanasuphot S, Charoensook O-A, Ungchusak K, Srijaggrawalwong A, Panthumachinda B. A field trial of inactivated mouse brain Japanese encephalitis vaccines produced in Thailand. Mosquito Borne Diseases Bulletin 1991;8(1):11-6.
12. *Rojanasuphot S, Charoensuk O, Kitprayura D, Likityingvara C, Limpisthien S, Boonyindee S, et al.A field trial of Japanese encephalitis vaccine produced in Thailand. Southeast Asian Journal of Tropical Medicine and Public Health 1989;20(4):653-4.
13. Ao 1983 Ao J, Yu YX, Tang YS, Cui BC, Jia DJ, Li HM. Selection of a better immunogenic and highly attenuated live vaccine strain of Japanese encephalitis II. Safety and immunogenecity of live vaccine SA14-14-2 observed in inoculated children. Chinese Journal of Microbiology and Immunology 1983;3:245-48.
14. Bhau 1988 Rao Bhau LN, Singh G, Gowal D, Saxena SN, Kobayashi M, Oya A, et al.Safety & efficacy of Japanese encephalitis vaccine produced in India. Indian Journal of Medical Research 1988;88:301-7.
15. Saxena SN, Bhau LN, Singh G, Gowal D, Sood YK, Misra CN, et al.Immune status of volunteers one year after administration of Japanese encephalitis vaccine produced in India. Indian Journal of Medical Research 1989;89:362-7.
16. Chen 1999 Chen HY, Ma FB, Zhang JL. Observation on safety of the live attenuated SA14-14-2 Japanese encephalitis vaccine. Chinese Journal of Epidemiology 1999;5(3).
17. Defraites 1999 Defraites RF, Gambel JM, Hoke CH Jr, Sanchez JL, Withers BG, Karabatsos N, et al.Japanese encephalitis vaccine (inactivated, BIKEN) in U.S. soldiers: immunogenicity and safety of vaccine administered in two dosing regimens. American Journal of Tropical Medicine and Hygiene 1999;61(2):288-93.
18. Gowal 1995 Gowal D, Tahlan AK. Evaluation of effectiveness of mouse brain inactivated Japanese encephalitis vaccine produced in India. Indian Journal of Medical Research 1995;102:267-71.
19. Guo 1998 Guo W, Li L, Wu Z. Analysis on the immuno-effects of two different Japanese encephalitis virus vaccines. Zhonghua Liu Xing Bing Xue Za Zhi 1998;19(2):97-9.
20. Hanna 2005 Hanna JN, Smith GA, McCulloch BG, Taylor CT, Pyke A, Brookes DL. An assessment of the interval between booster doses of Japanese encephalitis vaccine in the Torres Strait. Australian and New Zealand Journal of Public Health 2005;29(1):44-7.
21. Hazarika 1991 Hazarika NC. Project study on Japanese encephalitis vaccination at Gogamukh, Assam. Indian Pediatrics 1991;28(9):1029- 34.
22. Henderson 1984 Henderson A. Immunisation against Japanese encephalitis in Nepal: experience of 1152 subjects. Journal of the Royal Army Medical Corps 1984;130(3):188-91.
23. Intralawan 1993 Intralawan P, Paupunwatana S. Immunogenicity of low dose Japanese encephalitis vaccine (BIKEN) administered by the intradermal route: preliminary data. Asian Pacific Journal of Allergy and Immunology 1993;11(1):79-83.
24. Juang 1983 Juang RF, Okuno Y, Fukunaga T, Tadano M, Fukai K, Baba K, et al.Neutralizing antibody responses to Japanese encephalitis vaccine in children. Biken Journal 1983;26(1):25-34.
25. Kanesa-thasan 2000 Kanesa-thasan N, Smucny JJ, Hoke CH, Marks DH, Konishi E, Kurane I, et al.Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus - poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans. Vaccine 2000;19(4-5):483-91.
26. Kitchener 2006 Kitchener S, Nasveld P, Brennan L, Ward D. Comparative safety and efficacy of subcutaneous and intradermal administration of inactivated Japanese encephalitis vaccine during predeployment preparations in the Australian Defence Force. Military Medicine 2006;171(12): 1190-5.
27. Ku 1994 Ku CC, King CC, Lin CY, Hsu HC, Chen LY, Yueh YY, et al.Homologous and heterologous neutralization antibody responses after immunization with Japanese encephalitis vaccine among Taiwan children. Journal of Medical Virology 1994;44(2):122-31.
28. Lyons 2007 Lyons A, Kanesa-Thasan N, Kuschner RA, Eckels KH, Putnak R, Sun W, et al.A Phase 2 study of a purified, inactivated virus vaccine to prevent Japanese encephalitis. Vaccine 2007;25(17):3445-53.
29. Ma 1993 Ma X, Yu YX, Wang SG. Observations on safety and serological efficacy from a large scale field trial of Japanese encephalitis vaccine. Chinese Journal of Biologicals 1993;6(4):188-91.
30. Ma 2003 Ma FB, Zheng L, Bi C, Tao H, Zhou YL, Zhang JL, et al.Study on the strategy of Japanese encephalitis immunization using live attenuated vaccine combined with inactivated vaccine. Zhonghua Liu Xing Bing Xue Za Zhi 2003;24(2):113-5.
31. Mohan 1993 Mohan Rao CV, Risbud AR, Dandawate CN, Umarani UB, Ayachit VM, Rodrigues FM, et al.Serological response to Japanese encephalitis vaccine in a group of school children in South Arcot district of Tamil Nadu. Indian Journal of Medical Research 1993;97:53-9.
32. Nimmannitya 1995 Nimmannitya S, Hutamai S, Kalayanarooj S, Rojanasuphot S. A field study on Nakayama and Beijing strains of Japanese encephalitis vaccines. Southeast Asian Journal of Tropical Medicine and Public Health 1995;26(4):689-93.
33. Nothdurft 1996 Nothdurft HD, Jelinek T, Marschang A, Maiwald H, Kapaun A, Loscher T. Adverse reactions to Japanese encephalitis vaccine in travellers. Journal of Infection 1996;32(2):119-22.
34. Poland 1990 Poland JD, Cropp CB, Craven RB, Monath TP. Evaluation of the potency and safety of inactivated Japanese encephalitis vaccine in US inhabitants. Journal of Infectious Diseases 1990;161(5):878-82.
35. Rodrigues 1986 Rodrigues FM, Mohan Rao CV, Mandke VB, Pinto BD, Pavri K. Neutralizing antibody response to Japanese encephalitis inactivated mouse brain vaccine among laboratory personnel. Transactions of the Royal Society of Tropical Medicine and Hygiene 1986;80(2):301-4.
36. Sanchez 1990 Sanchez JL, Hoke CH, McCown J, DeFraites RF, Takafuji ET, Diniega BM, et al.Further experience with Japanese encephalitis vaccine. Lancet 1990;335(8695):972-3.
37. Sohn 1999 Sohn YM, Park MS, Rho HO, Chandler LJ, Shope RE, Tsai TF. Primary and booster immune responses to SA14-14-2 Japanese encephalitis vaccine in Korean infants. Vaccine 1999;17(18):2259-64.
38. Tsai 1998 Tsai TF, Yu YX, Jia LL, Putvatana R, Zhang R, Wang S, et al.Immunogenicity of live attenuated SA14-14-2 Japanese encephalitis vaccine - a comparison of 1- and 3-month immunization schedules. Journal of Infectious Diseases 1998;177(1):221-3.
39. Tseng 1999 Tseng CY, Hwang KP, Lin KH, Chen HY, Lu CC, Chiang CH. Comparison of immunogenicity of simultaneous and nonsimultaneous vaccination with MMR and JE vaccine among 15-month-old children. Acta Paediatrica Taiwanica 1999;40(3):161-5.
40. Xin 1988 Xin YY, Ming ZG, Peng GY, Jian A, Min LH. Safety of a live-attenuated Japanese encephalitis virus vaccine (SA14-14-2) for children. American Journal of Tropical Medicine and Hygiene 1988;39(2):214- 7.
41. Yamada 1986 Yamada A, Imanishi J, Juang RF, Fukunaga T, Okuno Y, Tadano M, et al.Trial of inactivated Japanese encephalitis vaccine in children with underlying diseases. Vaccine 1986;4(1):32-4.
42. Zhou 1999 Zhou B, Jia L, Xu X. A large-scale study on the safety and epidemiological efficacy of Japanese encephalitis (JE) live vaccine (SA14-14-2) in the JE endemic areas. Zhonghua Liu Xing Bing Xue Za Zhi 1999;20(1):38-41.
43. Acambis 2006 Acambis. Positive results from pivotal Phase 3 trials of Acambis' JE vaccine. www.acambis.co.uk/default.asp?id=1724 30 October 2006 (accessed March 2007).
44. Acambis 2007a Acambis. Acambis' JE vaccine meets and exceeds primary endpoint in pivotal Phase 3 efficacy trial. www.acambis.com/default. asp?id=1839 1 March 2007 (accessed March 2007).
45. Grachev 1984 Grachev VP, Sumarokov AA, Kharazian EG, Shkol'nik RIa, Karinskaia GA. Determination of the optimal dose of a cultured inactivated vaccine for preventing Japanese encephalitis. Zhurnal Mikrobiologii Epidemiologii i Immunobiologii 1984, (1):98-103.
46. Ishikawa 2005 Ishikawa T. Development of new Japanese encephalitis vaccine. Nippon Rinsho 2005;63(12):2133-7.
47. Sumarovkov 1983 Sumarovkov AA, Grachev VP, Kharazian EG, Shkol'nik RIa, Vorob'eva MS. Comparative study of the reactogenicity and immunogenicity of new Soviet and commercial vaccines for preventing Japanese encephalitis. Zhurnal Mikrobiologii Epidemiologii i Immunobiologii 1983, (9):74-9.
48. Acambis 2007b Acambis. ChimeriVax™-JE: A single-dose JE vaccine for endemic markets and travellers. www.acambis.co.uk/default.asp?id=936 (accessed March 2007).
49. Andersen 1991 Andersen MM. Ronne T. Side-effects with Japanese encephalitis vaccine. Lancet 1991;337(8748):1044.
50. Anonymous 2000 Anonymous. Japanese Encephalitis virus infection in mosquitoes and its epidemiological implications. Indian Council of Medical Research (ICMR) Bulletin April, 2000;30(4):1-7.
51. Barrett 1997 Barrett AD. Japanese encephalitis and dengue vaccines. Biologicals 1997;25(1):27-34.
52. Barrett 2001 Barrett AD. Current status of flavivirus vaccines. Annals of the New York Academy of Sciences 2001;951:262-71.
53. Berg 1997 Berg SW, Mitchell BS, Hanson RK, Olafson RP, Williams RP, Tueller JE, et al.Systemic reactions in U.S. Marine Corps personnel who received Japanese encephalitis vaccine. Clinical Infectious Diseases 1997;24(2):265-6.
54. Bista 2001 Bista MB, Banerjee MK, Shin SH, Tandan JB, Kim MH, Sohn YM, et al.Efficacy of single-dose SA 14-14-2 vaccine against Japanese encephalitis: a case control study. Lancet 2001;358(9284):791-5.
55. CDC 1993 Anonymous. Inactivated Japanese encephalitis virus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report 1993;42(RR-1):1-15.
56. Chambers 1997 Chambers TJ, Tsai TF, Pervikov Y, Monath TP. Vaccine development against dengue and Japanese encephalitis: report of a World Health Organization meeting. Vaccine 1997;15(14):1494-502.
57. Chang 2004 Chang GJ, Kuno G, Purdy DE, Davis BS. Recent advancement in flavivirus vaccine development. Expert Review of Vaccines 2004;3(2):199-220.
58. Chaudhuri 2006 Chaudhuri M. Chinese vaccine kills 10 children in UP. www.ndtv.com/morenews/showmorestory.asp?id=90630&frmsrch=1&txtsrch= chinese 25 July 2006 (accessed March 2007).
59. Endy 2002 Endy TP, Nisalak A. Japanese encephalitis virus: ecology and epidemiology. Current Topics in Microbiology and Immunology 2002;267:11-48.
60. Gajanana 1995 Gajanana A, Thenmozhi V, Samuel PP, Reuben R. A community-based study of subclinical flavivirus infections in children in an area of Tamil Nadu, India, where Japanese encephalitis is endemic. Bulletin of the World Health Organization 1995;73(2):237-44.
61. Glovax 2005 Glovax. Live-attenuated JE vaccine. www.glovax.com/99/default.asp?PageZoneNumber=3&GroupID=99-2&PageID= 37564u4887152778-99&CompanyID=99&ParentPageID=99 (accessed March 2007).
62. Hanna 1999 Hanna JN, Ritchie SA, Phillips DA, Lee JM, Hills SL, van den Hurk AF, et al.Japanese encephalitis in north Queensland, Australia, 1998. Medical Journal of Australia 1999;170(11):533-6.
63. Hennessy 1996 Hennessy S, Liu Z, Tsai TF, Strom BL, Wan CM, Liu HL, et al.Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control study. Lancet 1996;347(9015):1583-6.
64. Higgins 2006 Higgins JPT, Green S, editors. Highly sensitive search strategies for identifying reports of randomized controlled trials in MEDLINE. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]; Appendix 5b (accessed 1 March 2007).
65. Hoke 1992 Hoke CH Jr, Vaughn DW, Nisalak A, Intralawan P, Poolsuppasit S, Jongsawas V, et al.Effect of high-dose dexamethasone on the outcome of acute encephalitis due to Japanese encephalitis virus. Journal of Infectious Diseases 1992;165(4):631-7.
66. Hombach 2005 Hombach J, Solomon T, Kurane I, Jacobson J, Wood D. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004. Vaccine 2005;23(45):5205-11.
67. Huy 1994 Huy BV, Tu HC, Luan TV, Lindqvist R. Early mental and neurological sequelae after Japanese B encephalitis. The Southeast Asian Journal of Tropical Medicine and Public Health 1994;25(3):549-53.
68. Igarashi 2002 Igarashi A. Control of Japanese encephalitis in Japan: immunization of humans and animals, and vector control. Current Topics in Microbiology and Immunology 2002;267:139-52.
69. IOM 1986 Institute of Medicine. The prospects for immunizing against Japanese encephalitis virus. Diseases of importance in developing countries: Establishing priorities; Volume II, Diseases of importance in developing countries. Washington, DC: National Academy Press, 1986:223-40.
70. Jacobson 2006 Jacobson J. Japanese encephalitis (JE) vaccine in India (Uttar Pradesh)(02): Vaccine Safety, RFI. ProMED-mail: Archive number 20060727.2064 26 July 2006 (accessed March 2007).
71. Juni 2001 Juni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ 2001;323(7303):42-6.
72. Khan 1996 Khan SA, Narain K, Handigue R, Dutta P, Mahanta J, Satyanarayana K, et al.Role of some environmental factors in modulating seasonal abundance of potential Japanese encephalitis vectors in Assam, India. The Southeast Asian Journal of Tropical Medicine and Public Health 1996;27(2):382-91.
73. Kumar 1993 Kumar R, Mathur A, Singh KB, Sitholey P, Prasad M, Shukla R, et al.Clinical sequelae of Japanese encephalitis in children. The Indian Journal of Medical Research 1993;97:9-13.
74. Kurane 2000 Kurane I, Takasaki T. Immunogenicity and protective efficacy of the current inactivated Japanese encephalitis vaccine against different Japanese encephalitis virus strains. Vaccine 2000;18(2):33-5.
75. Kurane 2005 Kurane I. Evaluation of mouse brain-derived, inactivated Japanese encephalitis vaccine. Uirusu 2005;55(2):307- 12.
76. Lacey 1990 Lacey LA, Lacey CM. The medical importance of riceland mosquitoes and their control using alternatives to chemical insecticides. Journal of the American Mosquito Control Association 1990;2:1-93.
77. Luo 1994 Luo D, Yin H, Xili L, Song J, Wang Z. The efficacy of Japanese encephalitis vaccine in Henan, China: a case-control study. Southeast Asian Journal of Tropical Medicine and Public Health 1994;25(4):643-6.
78. Markoff 2000 Markoff L. Points to consider in the development of a surrogate for efficacy of novel Japanese encephalitis virus vaccines. Vaccine 2000;18(suppl 2):26-32.
79. Matsunaga 1999 Matsunaga Y, Yabe S, Taniguchi K, Nakayama M, Kurane I. Current status of Japanese encephalitis in Japan. Kansenshogaku Zasshi 1999;73(2):97-103.
80. Monath 2002a Monath TP. Japanese encephalitis vaccines: current vaccines and future prospects. Current Topics in Microbiology and Immunology 2002;267:105-38.
81. Nothdurft 1996 Nothdurft HD, Jelinek T, Marschang A, Maiwald H, Kapaun A, Loscher T. Adverse reactions to Japanese encephalitis vaccine in travellers. Journal of Infection 1996;32(2):119-22.
82. Ohrr 2005 Ohrr H, Tandan JB, Sohn YM, Shin SH, Pradhan DP, Halstead SB. Effect of single dose of SA 14-14-2 vaccine 1 year after immunisation in Nepalese children with Japanese encephalitis: a case-control study. Lancet 2005;366(9494):1375-8.
83. Okabe 2005 Okabe N. Background of recent JE vaccine issues. Uirusu 2005;55(2):303-6.
84. PATH 2006a PATH. Vaccine resource library: Japanese encephalitis vaccine. www.path.org/vaccineresources/japanese_encephalitis-vaccine.php (accessed August 2006).
85. PATH 2006b PATH. Historic protection for Asia's children: PATH and our partners take action to eliminate Japanese encephalitis. www.path.org/projects/japanese_encephalitis_project.php (accessed August 2006).
86. Peiris 1993 Peiris JS, Amerasinghe FP, Arunagiri CK, Perera LP, Karunaratne SH, Ratnayake CB, et al.Japanese encephalitis in Sri Lanka: comparison of vector and virus ecology in different agro-climatic areas. Transactions of the Royal Society of Tropical Medicine and Hygiene 1993;87(5):541-8.
87. Plesner 1996 Plesner AM, Arlien-Soborg P, Herning M. Neurological complications and Japanese encephalitis vaccination. Lancet 1996;348(9021):202-3.
88. Plesner 1997 Plesner AM, Ronne T. Allergic mucocutaneous reactions to Japanese encephalitis vaccine. Vaccine 1997;15(11):1239-43.
89. Plesner 2000 Plesner A, Ronne T, Wachmann H. Case-control study of allergic reactions to Japanese encephalitis vaccine. Vaccine 2000;18(17):1830-6.
90. Reuben 1992 Reuben R, Thenmozhi V, Samuel PP, Gajanana A, Mani TR. Mosquito blood feeding patterns as a factor in the epidemiology of Japanese encephalitis in southern India. American Journal of Tropical Medicine and Hygiene 1992;46(6):654-63.
91. Ruff 1991 Ruff TA, Eisen D, Fuller A, Kass R. Adverse reactions to Japanese encephalitis vaccine. Lancet 1991;338(8771):881-2.
92. Schneider 1974 Schneider R J, Firestone MH, Edelman R, Chieowanich P, Pornpibul R. Clinical sequelae after japanese encephalitis: a one year follow-up study in Thailand. Southeast Asian Journal of Tropical Medicine and Public Health 1974;5(4):560-8.
93. Shlim 2002 Shlim DR, Solomon T. Japanese encephalitis vaccine for travelers: exploring the limits of risk. Clinical Infectious Diseases 2002;35(2):183-8.
94. Sohn 2000 Sohn YM. Japanese encephalitis immunization in South Korea: past, present, and future. Emerging Infectious Dieseases 2000;6(1):17-24. [MEDLINE: 1080-6040].
95. Solomon 2000 Solomon T, Dung NM, Kneen R, Gainsborough M, Vaughn DW, Khanh VT. Japanese encephalitis. Journal of Neurology, Neurosurgery and Psychiatry 2000;68(4):405-15. [MEDLINE: 0022-3050].
96. Solomon 2002 Solomon T, Vaughn DW. Pathogenesis and clinical features of Japanese encephalitis and West Nile virus infections. Current Topics in Microbiology and Immunology 2002;267:171-94.
97. Srivastava 2001 Srivastava AK, Putnak JR, Lee SH, Hong SP, Moon SB, Barvir DA, et al.A purified inactivated Japanese encephalitis virus vaccine made in Vero cells. Vaccine 2001;19(31):4557-65.
98. Sunish 2001 Sunish IP, Reuben R. Factors influencing the abundance of Japanese encephalitis vectors in ricefields in India - I. Abiotic. Medical and Veterinary Entomology 2001;15(4):381-92.
99. Takagi 1997 Takagi M, Suwonkerd W, Tsuda Y, Sugiyama A, Wada Y. Effects of rice culture practices on the abundance of Culexmosquitoes (Diptera: Culicidae) in northern Thailand. Journal of Medical Entomology 1997;34(3):272-6. [MEDLINE: 0022-2585].
100. Takahashi 2000 Takahashi H, Pool V, Tsai TF, Chen RT. Adverse events after Japanese encephalitis vaccination: review of post-marketing surveillance data from Japan and the United States. The VAERS Working Group. Vaccine 2000;18(26):2963-9.
101. Tsai 1994 Tsai TF, Chang GJ, Yu YX. Japanese encephalitis vaccines. Vaccines. 2nd Edition. Philadelphia: Saunders W.B, 1994:671-713.
102. Tsai 2000 Tsai TF. New initiatives for the control of Japanese encephalitis by vaccination: Minutes of a WHO/CVI meeting, Bangkok, Thailand, 13-15 October 1998. Vaccine 2000;18 Suppl 2:1-25.
103. Vaughn 1992 Vaughn DW, Hoke CH Jr. The epidemiology of Japanese encephalitis: prospects for prevention. Epidemiologic Reviews 1992;14:197-221.
104. WHO 1998 World Health Organization. Japanese encephalitis vaccines. WHO position paper. Weekly Epidemiological Record 1998;73(44):337-44.
105. WHO 2003 WHO Initiative for Vaccine Research. State of the art of new vaccines: research and development (www.who.int/vaccine_research/ documents/en/stateofart_excler.pdf ). Geneva: World Health Organization, 2003.
106. WHO 2005a World Health Organization. Global Advisory Committee on Vaccine Safety, 9-10 June 2005. Weekly Epidemiological Record 2005;80(28):242-3.
107. WHO 2005b WHO Initiative for Vaccine Research. New vaccines against infectious diseases: research and development status; April 2005, updated February 2006. www.who.int/vaccine_research/documents/en/Status_Table. pdf (accessed August 2006).
108. Wu 1999 Wu YC, Huang YS, Chien LJ, Lin TL, Yueh YY, Tseng WL, et al.The epidemiology of Japanese encephalitis on Taiwan during 1966-1997. American Journal of Tropical Medicine and Hygiene 1999;61(1):78- 84.
109. Yang 2006 Yang SE, Pan MJ, Tseng HF, Liau MY. The efficacy of mouse-brain inactivated Nakayama strain Japanese encephalitis vaccine - results from 30 years experience in Taiwan. Vaccine 2006;24(14):2669-73.
110. Zhou 2001 Zhou B, Zhang M, Chen P, et al.An 11 year follow-up of epidemiological effect Japanese encephalitis vaccine, live (SA14-14-2). Chinese Journal of Biologicals 2001; Vol. 14(3) (translated by Chengdu Institute of Biologic Products).